These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 15452739)

  • 1. Approval times and the safety of new pharmaceuticals.
    Rudholm N
    Eur J Health Econ; 2004 Dec; 5(4):345-50. PubMed ID: 15452739
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Canadian and US drug approval times and safety considerations.
    Rawson NS; Kaitin KI
    Ann Pharmacother; 2003 Oct; 37(10):1403-8. PubMed ID: 14519031
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A primer of drug safety surveillance: an industry perspective. Part I: Information flow, new drug development, and federal regulations.
    Allan MC
    J Pharm Technol; 1992; 8(4):162-7. PubMed ID: 10121011
    [TBL] [Abstract][Full Text] [Related]  

  • 4. FDA attempting to overcome major roadblocks in monitoring drug safety.
    Zielinski SL
    J Natl Cancer Inst; 2005 Jun; 97(12):872-3. PubMed ID: 15956645
    [No Abstract]   [Full Text] [Related]  

  • 5. After Avandia, some seek split in drug approval and monitoring.
    Dolgin E
    Nat Med; 2010 Aug; 16(8):831. PubMed ID: 20689527
    [No Abstract]   [Full Text] [Related]  

  • 6. Safety in numbers--monitoring risk in approved drugs.
    Okie S
    N Engl J Med; 2005 Mar; 352(12):1173-6. PubMed ID: 15788493
    [No Abstract]   [Full Text] [Related]  

  • 7. US FDA's safety monitoring of drugs with expedited approval.
    Furlow B
    Lancet Oncol; 2016 Mar; 17(3):281. PubMed ID: 26831290
    [No Abstract]   [Full Text] [Related]  

  • 8. Post-market surveillance of GM foods: applicability and limitations of schemes used with pharmaceuticals and some non-GM novel foods.
    Wal JM; Hepburn PA; Lea LJ; Crevel RW
    Regul Toxicol Pharmacol; 2003 Aug; 38(1):98-104. PubMed ID: 12878059
    [TBL] [Abstract][Full Text] [Related]  

  • 9. What do stakeholders think about pharmacovigilance?
    Edwards IR; Graedon T
    Drug Saf; 2010 Aug; 33(8):619-21. PubMed ID: 20635819
    [No Abstract]   [Full Text] [Related]  

  • 10. Pharmaceuticals and medical devices: FDA oversight. Issue brief.
    Berry MD
    Issue Brief Health Policy Track Serv; 2012 Dec; ():1-79. PubMed ID: 23297449
    [No Abstract]   [Full Text] [Related]  

  • 11. Bad medicine. Monitoring programs target substandard drugs.
    Grens K
    Mod Healthc; 2013 May; 43(20):30-1. PubMed ID: 23947275
    [No Abstract]   [Full Text] [Related]  

  • 12. The unfinished business of U.S. drug safety regulation.
    Evans BJ; Flockhart DA
    Food Drug Law J; 2006; 61(1):45-63. PubMed ID: 16838457
    [No Abstract]   [Full Text] [Related]  

  • 13. How to avoid another 'Vioxx'.
    Frantz S
    Nat Rev Drug Discov; 2005 Jan; 4(1):5-7. PubMed ID: 15690595
    [No Abstract]   [Full Text] [Related]  

  • 14. FDA's monitoring of postmarketing studies probed.
    Young D
    Am J Health Syst Pharm; 2006 Aug; 63(16):1485-6. PubMed ID: 16896075
    [No Abstract]   [Full Text] [Related]  

  • 15. Post-marketing drug safety in the era of genomic medicine.
    Zavras AI
    J Dent Res; 2005 Feb; 84(2):105-6. PubMed ID: 15668326
    [No Abstract]   [Full Text] [Related]  

  • 16. Timeliness of Postmarket Studies for New Pharmaceuticals Approved Between 2009 and 2012: a Cross-Sectional Analysis.
    Wallach JD; Egilman AC; Ross JS; Woloshin S; Schwartz LM
    J Gen Intern Med; 2019 Apr; 34(4):492-495. PubMed ID: 30543020
    [No Abstract]   [Full Text] [Related]  

  • 17. Quality, safety and efficacy of follow-on biologics in Japan.
    Yamaguchi T; Arato T
    Biologicals; 2011 Sep; 39(5):328-32. PubMed ID: 21890377
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Experiences and reflections in the paediatric context - From label to delivery of an innovative treatment: what a journey! (1)].
    Cancès C
    Med Sci (Paris); 2019 Mar; 35 Hors série n° 1():32-34. PubMed ID: 30943159
    [No Abstract]   [Full Text] [Related]  

  • 19. Opening Pandora's pillbox: using modern information tools to improve drug safety.
    Gottlieb S
    Health Aff (Millwood); 2005; 24(4):938-48. PubMed ID: 16012136
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Uptake of new drugs in the early post-approval period in the Mini-Sentinel distributed database.
    Mott K; Graham DJ; Toh S; Gagne JJ; Levenson M; Ma Y; Reichman ME
    Pharmacoepidemiol Drug Saf; 2016 Sep; 25(9):1023-32. PubMed ID: 27146123
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.